ReviewFrontiers in cell and developmental biology2026
Microneedle-guided monitoring and therapy in chronic limb-threatening ischemia.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic limb-threatening ischemia (CLTI) represents the most severe form of peripheral artery disease, with high risks of infection, tissue loss, amputation, and mortality. Continuous or high-frequency monitoring could improve early detection of deterioration between clinic visits, yet current perfusion tests are limited by variability and episodic use. This mini review focuses on microneedle-enabled access to interstitial fluid for trend-based monitoring and local therapy in CLTI. Evidence is synthesized linking oxygenation, lactate, and pH to ischemic pathophysiology and infection risk, and microneedle sensing approaches for these core markers are outlined. Local delivery design patterns that support staged care-stabilizing the microenvironment, controlling infection, and promoting regeneration-are summarized while maintaining sensing interpretability. Key translation barriers include drift and calibration during chronic wear, safety in fragile ischemic skin, and integration with clinical workflows. Minimally sufficient, trend-oriented sensing combined with phase-matched local interventions provides a pragmatic pathway toward clinically actionable "sense-treat" microneedle systems for CLTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.